Skip to main content
EVAX
NASDAQ Life Sciences

MSD Licenses Evaxion's EVX-B3, Cancer Vaccine EVX-01 Shows Strong Phase 2 Data, Cash Runway to H2 2027

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$3.17
Mkt Cap
$19.645M
52W Low
$1.2
52W High
$12.15
52W Position info
164% above low
Off High info
74% below high
Rel. Volume
Market data snapshot near publication time

EVAX has more than doubled off its 52-week low of $1.2.

Summary

Evaxion announced a comprehensive business update and full-year 2025 financial results, highlighting a transformational year. Key achievements include the historic licensing of its infectious disease vaccine candidate EVX-B3 by MSD, impressive two-year Phase 2 data for its personalized cancer vaccine EVX-01, and the addition of two new candidates (EVX-04 and EVX-B4) to its R&D pipeline. The company also significantly strengthened its financial position through partnerships and capital market activities totaling over $30 million, extending its cash runway into the second half of 2027. This announcement follows a 20-F filing earlier today which indicated significant financial improvement for 2025, with this news release providing the crucial operational and pipeline details that underpin that financial strength. For a micro-cap biotech, the MSD licensing deal represents a major validation and potential revenue stream, while the positive Phase 2 data for EVX-01 is a significant de-risking event for its lead oncology asset. The extended cash runway into H2 2027 substantially alleviates near-term financing concerns. Investors will now watch for further EVX-01 data, the planned Phase 1 trial for EVX-04, and continued partnership developments as the company expands its AI-Immunology platform.

At the time of this announcement, EVAX was trading at $3.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.6M. The 52-week trading range was $1.20 to $12.15. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

EVAX - Latest Insights

EVAX
Nov 19, 2026, 7:05 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.54
Real-time Price: $2.32 info
Change: -$0.220 (-9%) info
Market Cap: $16.931M info
EVAX
Nov 19, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.82
Real-time Price: $2.32 info
Change: -$0.4994 (-18%) info
Market Cap: $16.931M info
EVAX
Oct 23, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.32 info
Change: -$1.72 (-43%) info
Market Cap: $16.931M info
EVAX
Oct 19, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.32 info
Change: -$0.930 (-29%) info
Market Cap: $16.931M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.47
Real-time Price: $2.32 info
Change: -$1.15 (-33%) info
Market Cap: $16.931M info